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Commentary
Translational research of complex human 
  disease is dependent on the availability of 
well-annotated genetic materials for identify-
ing susceptibility loci, viable bio  specimens for 
functional single-nucleotide poly  morphism 
(SNP) assays, and research subjects for in vivo 
pheno  typing and toxicity studies. A wide spec-
trum of human tissue repositories are available 
today for genomic and proteomic research. 
These repositories, in combination with high-
throughput geno  typing and bioinformatics, 
have greatly advanced the understanding of 
genetic alterations and biological pathways 
that influence human disease. However, iden-
tifying appropriate human research subjects 
with geno  types of interest for follow-up stud-
ies remains problematic. With this in mind, 
we have created a unique resource to facili-
tate translational research of environmental 
disease. This is a large-scale pheno  type-by-
geno  type regis  try consisting of > 15,000 indi-
viduals of diverse sex, age, race, and ethnicity, 
named the Environmental Polymorphisms 
Registry (EPR) [Chulada et al. 2008; 
National Institute of Environmental Health 
Sciences (NIEHS) 2011]. 
The EPR is a linked DNA biorepository. 
DNA is isolated from blood samples donated 
by the subjects and linked to their identities 
through a personal identification number. 
Compared with anonymous bio  repositories, 
linked resources such as the EPR are more use-
ful in translational research. With the former, 
information on the donors’ identities is perma-
nently destroyed, precluding follow-up of the 
same individuals known to have functionally 
rele  vant geno  types. With linked repositories 
such as the EPR, subjects with geno  types of 
interest can be asked to participate in all phases 
of translational research, from basic labora-
tory ex vivo cell pheno  typing studies requiring 
viable tissue to comprehensive in vivo clinical 
pheno  typing and/or toxicity studies. Other 
types of studies are possible, including cohort 
studies of disease risk, and interventional and 
personalized medicine trials.
The EPR has been described previously 
(Chulada et al. 2008; NIEHS 2011). Here we 
report on our progress in establishing the EPR 
since 2008 and its use in several follow-up 
studies. We also describe a major project 
to investigate potential susceptibility loci in 
87 environmental response genes using EPR 
subjects. This project (the EPR Consortium 
Project) is being conducted in two phases. In 
the first phase, EPR subjects are screened for 
potentially significant loci using high-through-
put geno  typing methods. In the second phase, 
subgroups with shared geno  types are asked 
to participate in various follow-up studies to 
examine cellular and clinical pheno  typic dif-
ferences. Many of the studies involve exposing 
subjects (or cells) to environ  mental stimuli and 
examining gene × environ  ment inter  actions. 
The purpose of this commentary is to illustrate 
how linked resources like the EPR facilitate 
geno  type-driven translational research of envi-
ronmental disease, and help scientists identify 
at-risk populations and develop strategies for 
preventing and treating disease.
EPR Progress since 2008
The EPR was designed to facilitate geno  type-
driven research. During enrollment, subjects 
consent to anonymous phase 1 genetic screen-
ing and to being reidentified and called back 
for phase 2 pheno  typing studies on the basis 
of their geno  types. Phase 2 pheno  typing stud-
ies are voluntary; subjects can choose to take 
part in some studies and not in others. No 
subjects are reidentified for phase 2 studies 
until a protocol is developed and reviewed 
by an advisory oversight committee (the 
EPR Steering Committee), scientific review 
committee, and institutional review board 
(IRB). EPR methods, human subjects protec-
tion measures, advisory oversight, and other 
aspects have been described in detail previ-
ously (Chulada et al. 2008).
EPR recruitment began in 2005 and 
initially encompassed counties surrounding 
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Ba c k g r o u n d: Dissecting complex disease has become more feasible because of the availability of 
large-scale DNA resources and advances in high-throughput genomic technology. Although these 
tools help scientists identify potential susceptibility loci, subjects with relevant geno  types are needed 
for clinical pheno  typing and toxicity studies.
oB j e c t i v e: We have developed a resource of subjects and their DNA to use for translational 
research of environmental disease.
Me t h o d s : More than 15,000 individuals of diverse sex, age, race, and ethnicity were recruited from 
North Carolina. DNA was isolated from their blood and coded with personal identification num-
bers linked to their identities. This linked resource of subjects and their DNA—the Environmental 
Polymorphism Registry (EPR)—allows scientists to screen for individuals with geno  types of interest 
and invite them to participate in follow-up studies.
discussion: The EPR is a pheno  type-by-geno  type resource designed to facilitate translational studies   
of environmental disease. Based on their geno  types, subjects are invited to participate at all levels 
of research, from basic laboratory ex vivo cell pheno  typing experiments that require viable tissue 
to in vivo observational studies and clinical trials. Here we report on progress of the EPR since 
2008. We also describe a major effort at the National Institute of Environmental Health Sciences 
(NIEHS) to investigate susceptibility loci in 87 environ  mental response genes and gene × environ-
ment interactions using EPR resources. 
co n c l u s i o n: The EPR is a unique and novel resource and is ideal for geno  type-driven translational 
research of environmental disease. We expect that it will serve as a model for future resources. Such 
tools help scientists attain their ultimate goals: to identify at-risk populations and develop strategies 
for preventing and treating human disease. 
key w o r d s : DNA biorepository, environmental response gene, environmental risk assessment, geno-
types, pheno  type-by-geno  type, polymorphisms, toxicity studies, translational research. Environ Health 
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Research Triangle Park, North Carolina. The 
goal was to enroll 3,000–5,000 subjects per 
year until 20,000 subjects were recruited. To 
meet this goal, we expanded recruitment to 
outlying counties in 2007; by 2009 we had 
enrolled almost 15,000 subjects. Thereafter, 
the rate of recruitment decreased because of 
budgetary constraints.
At the time of our first report, the EPR 
consisted of 7,788 subjects (Chulada et al. 
2008). Today, there are twice that num-
ber (n = 15,376 subjects of diverse sex, age, 
race, and ethnicity). These include 65.5% 
Caucasians, 24.7% African Americans, and 
smaller percentages of other races (Figure 1A). 
The racial makeup is representative of North 
Carolina based on 2000 Census data (U.S. 
Census Bureau 2011) (African Americans 
are somewhat over  represented). A signifi-
cant proportion of EPR subjects (5.2%) are 
Hispanic or Latino (Figure 1A), and most 
(61.6%) are female (Table 1). Most subjects 
are young (18–40 years of age) or middle-age 
(41–60 years) adults (Table 1). This makes 
them ideal for studying adult-onset disease.
The EPR is a long-term registry; subjects 
have agreed to be recontacted for follow-up 
studies for 25 years after enrollment. Therefore, 
we maintain current contact information on 
as many subjects as possible using a combina-
tion of annual mailings, telephone calls, and 
tracing (Chulada et al. 2008). EPR subjects 
are considered active (for phase 2 studies) if 
they are newly recruited (within a year) or have 
been successfully recontacted within the past 
year. Recontacting efforts have been successful; 
80.5% (n = 12,375) of the EPR population 
remains active (recontactable) since recruit-
ment began in 2005 (Figure 1B).
Most EPR subjects reside in the Research 
Triangle Park region and can readily travel 
to the NIEHS or other research centers for 
follow-up studies. Figure 2 depicts the distribu-
tion of subjects in North Carolina by race, eth-
nicity, and sex. About 8.1% of active subjects 
live out of state (most in Virginia and South 
Carolina, which border North Carolina), and 
0.1% live outside the United States.
EPR Consortium Project
Phase 1: genetic screening. The EPR 
Consortium Project is a large translational 
research project initiated at the NIEHS 
by a multi  disciplinary team of basic scien-
tists, geneticists, toxicologists, clinicians, 
and bio  statisticians (the EPR Consortium). 
Consortium members have selected 87 genes 
for study that, based on cell culture, animal, 
Table 1. EPR population by sex and age.
Sex (%)
Age (years) Female Male NR
18–40 23.5 14.3 0.2
41–60 25.5 13.6 0.7
≥ 61 12.0 8.0 1.0
NR 0.6 0.4 0.2
Total 61.6 36.3 2.1
NR, not reported. Percentages are based on an EPR 
population of 15,376 subjects. 
Figure 1. Demographics of the entire EPR population (A) and of the recontactable EPR population (B). Numbers beside bars represent percentage of the population. 
a37.5% female, 22.6% male, and 0.7% not reported. b14.2% female, 7.2% male, and 0.2% not reported. c40.8% female, 24.1% male, and 0.7% not reported. d13.4% female, 5.9% male, and 
0.1% not reported. 
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and/or human studies, are candidate genes for 
asthma, athero  sclerosis, cancer, auto  immune 
disease, aging, and other conditions. Most are 
environmental response genes that work in 
concert with environ  mental exposures to elicit 
a pheno  type. Examples include cytochromes 
P450 (CYP2J2, CYP2C8, CYP2C9), which are 
involved in xeno  biotic or drug metabolism, and 
AhR (aryl hydro  carbon receptor), ARNT (AhR 
nuclear trans  locator), and AhRR (AhR repres-
sor), which mediate the effects of poly  cyclic 
aromatic hydro  carbons and other endocrine-   
and immune-disrupting xeno  biotics.
From the 87 genes, we identified 717 SNPs 
that were predicted to alter protein sequence 
and/or function, are in evolutionarily con-
served regu  la  tory regions, or tag European and 
African ancestral haplotypes. About 70% of 
these SNPs can be found in dbSNP [National 
Center for Biotechnology Information (NCBI) 
2010b] and HapMap databases (NCBI 2010a) 
and were selected using SNPselector (Xu et al. 
2005) or based on a priori functional signifi-
cance. The other 30% of SNPs are novel and 
potentially significant based on research con-
ducted by individual consortium members. 
An additional 51 sex and ancestral informative 
markers (AIMs) are being geno  typed and will 
be compared with self-reported sex and race 
for quality control. The AIMs also will be used 
to meas  ure admixture in the population and to 
adjust for population stratification.
In this first round of geno  typing, 4,000 
subjects are being screened using custom high-
throughput 384-plex Illumina arrays (Illumina, 
Inc., San Diego, CA). The 4,000 consists of 
approximately 500 subjects of Hispanic or 
Latino ethnicity and equal numbers of males 
and females of African and European ances-
try. Important aims of phase 1 geno  typing 
are to assess geno  type frequency in the EPR 
population stratified by race, ethnicity, and 
sex, inform phase 2 study design, and iden-
tify appropriate subjects for follow-up studies. 
We expect that most (but not all) geno  typing 
studies will lead to follow-up pheno  typing 
studies, and in these situations we screen only 
active subjects who can be readily recontacted. 
Nonactive EPR subjects can be used in geno-
typing projects where follow-up is not impor-
tant, for example, in simple assessments of 
SNP prevalence rates or in approximation of 
haplo  types using statistical methods (Stephens 
et al. 2001).
Phase 2: pheno  typing. Based on phase 1 
results, subgroups of EPR subjects with shared 
geno  types are invited to participate in various 
phase 2 studies. The studies vary in hypothe-
ses, and their design depends on minor allele 
frequencies, population stratification, and 
gene penetrance. Cell pheno  typing studies 
have been the most common type of fol-
low-up study proposed to date, as we expected 
in early-phase EPR research. Subjects with 
geno  types of interest are invited to donate 
viable tissue for basic laboratory experi  ments 
aimed at charac  terizing some molecular or 
functional attribute of the geno  type. Here 
statistical power depends on the allele fre-
quency and magnitude of the biochemical 
or molecular effect, and small numbers of 
subjects are usually adequate. Higher levels 
of follow-up studies have been proposed and 
include observational or interventional clini-
cal trials, epidemiological surveys, and cohort 
studies of disease risk. Four follow-up studies 
are described below to illustrate the usefulness 
of the EPR in translational research. The first 
three have been approved by the NIEHS IRB 
and are under way; the fourth is under review.
As described above, cell pheno  typing studies   
are a common use of EPR resources. In the 
first example, we screened subjects for SNPs 
in p53 response elements of p53 downstream 
genes (FLT1, TLR8, RRM1, MDM2). During 
a follow-up study, these subjects were asked 
to donate blood for viable lymphocytes to test 
the potential of the SNPs to alter cell func-
tion, p53 promoter occupancy, and trans-
activation of downstream genes by p53 tumor 
protein (Bond et al. 2004; Menendez et al. 
2006; Murphy 2006; Tomso et al. 2005). 
We treated the cells ex vivo to induce p53-
mediated stress and DNA damage and exam-
ined them for gene expression by micro  array 
technology. 
Figure 2. Distribution of the recontactable EPR population in North Carolina by race (A), ethnicity (B), and 
sex (C). The size of each pie represents an estimate of the number of EPR subjects living in the region 
under the pie. Pie slices represent the proportions of subjects of different races (A), ethnicity (B), and sex 
(C). Abbreviations: AA, African American; AIAN, American Indian/Alaska Native; NHOPI, Native Hawaiian/
other Pacific Islander; NR, not reported. 
Columbus
Bladen
Sampson
Cumberland Richmond
Wayne
Greene
Lenoir
Jones
Craven
Wilson
Edgecombe
Nash
Northampton
Southampton Suffolk
Chesapeake
Chesapeake
Halifax
Warren 
Franklin
Granville
Hoke
Scotland
Robeson
Moore
Montgomery
Davidson Davie
Caswell Rockingham Stokes Surry
Ashe          
Allegheny
Wilkes
Alexander
Catawba
Caldwell
Watauga
Avery
Burke McDowell
Henderson
Transylvania
Greenville
Spartanburg
Pickens
Oconee
Stephens
White
Lumpkin
Union
Towns
Banks
Hall
Jackson
Barrow
Oconee Oglethorpe
Athens
Columbia
Charlotte 
Jackson
Winston Salem
Fayetteville
Madison
Hart
Franklin
Elbert
Rabun
Cherokee
York
Union  Chester
Lancaster  Chesterfield
Marlboro
Dillon
Marion
Florence
St
Saluda
McCormick
Lee
Darlington Kershaw
Newberry
Fairfield
Laurens
Anderson
Greenwood
Abbeville
Rutherford
Buncombe
Haywood
Macon Clay
Graham
Knoxville
Swain
Madison
Cocke
Sevier
Jefferson
Greene
Washington Carter
Johnson
Sullivan
Hawkins
Hancock
Lee Scott Washington Grayson
Patrick Henry
Pittsylvania Halifax
Mecklenburg
Brunswick
Carroll
Hamblen Grainger Union
Knox
Blount
Mitchell
Yancey
Cleveland
Polk
Iredell
Anson
Stanly
Mecklenburg
Union
Cabarrus
Lincoln
Gaston
Rowan
New Hanover
Pender
Duplin
Onslow
Carteret
Pamlico
Beaufort
Pitt
Hyde
Martin
Hertford
Gates
Perquimans
Bertie
Camden    
Currituck
Washington Tyrrell Dare
Oconee
Stephens ens
White
mpkin
Banks
Hall
Jackson
Barrow
Olth
Athens
Madison
Hart
Franklin
Elbert
McCorm Mc
Anderson
Abbeville
m
Oglethorpe McCorm Mc
Columbus
Bladen
Sampson
Cumberland Richmond
Wayne
Greene
Lenoir
Jones
Craven
Wilson
Edgecombe
Nash
Northampton
Southampton Suffolk
Chesapeake
Chesapeake
Halifax
Warren 
Franklin
Granville
Hoke
Scotland
Robeson
Moore
Montgomery
Davidson Davie
Caswell Rockingham Stokes Surry
Ashe          
Allegheny
Wilkes
Alexander
Catawba
Caldwell
Watauga
Avery
Burke McDowell
Henderson
Transylvania
Greenville
Spartanburg
Pickens
Oconee
Stephens
White
Lumpkin
Union
Towns
Banks
Hall
Jackson
Barrow
Oconee Oglethorpe
Athens
Columbia
Charlotte 
Jackson
Winston Salem
Fayetteville
Madison
Hart
Franklin
Elbert
Rabun
Cherokee
York
Union  Chester
Lancaster  Chesterfield
Marlboro
Dillon
Marion
Florence
Horry Sumter Richland
Saluda
McCormick
Lee
Darlington Kershaw
Newberry
Fairfield
Laurens
Anderson
Greenwood
Abbeville
Rutherford
Buncombe
Haywood
Macon Clay
Graham
Knoxville
Swain
Madison
Cocke
Sevier
Jefferson
Greene
Washington Carter
Johnson
Sullivan
Hawkins
Hancock
Lee Scott Washington Grayson
Patrick Henry
Pittsylvania Halifax
Mecklenburg
Brunswick
Carroll
Hamblen Grainger Union
Knox
Blount
Mitchell
Yancey
Cleveland
Polk
Iredell
Anson
Stanly
Mecklenburg
Union
Cabarrus
Lincoln
Gaston
Rowan
Brunswick
New Hanover
Pender
Duplin
Onslow
Carteret
Pamlico
Beaufort
Pitt
Hyde
Martin
Hertford
Gates
Perquimans
Bertie
Camden    
Currituck
Washington Tyrrell Dare
Stephens ens
White
mpkin
Banks
Hall
Jackson
Barrow
Oconee Oglethorpe
Athens
Madison
Hart
Franklin
Elbert
S
McCormick McC
Lauren
Anderson
Greenwood
Abbeville
Whit
m
S
s
d
Columbus
Bladen
Sampson
Cumberland Richmond
Wayne
Greene
Lenoir
Jones
Craven
Wilson
Edgecombe
Nash
Northampton
Southampton Suffolk
Chesapeake
Chesapeake
Halifax
Warren 
Franklin
Granville
Hoke
Scotland
Robeson
Moore
Montgomery
Davidson Davie
Caswell Rockingham Stokes Surry
Ashe          
Allegheny
Wilkes
Alexander
Catawba
Caldwell
Watauga
Avery
Burke McDowell
Henderson
Transylvania
Greenville
Spartanburg
Pickens
Oconee
Stephens
White
Lumpkin
Union
Towns
Banks
Hall
Jackson
Barrow
Oconee Oglethorpe
Athens
Columbia
Charlotte 
Jackson
Winston Salem
Fayetteville
Madison
Hart
Franklin
Elbert
Rabun
Cherokee
York
Union  Chester
Lancaster  Chesterfield
Marlboro
Dillon
Marion
Florence
Horry Sumter Richland
Saluda
McCormick
Lee
Darlington Kershaw
Newberry
Fairfield
Laurens
Anderson
Greenwood
Abbeville
Rutherford
Buncombe
Haywood
Macon Clay
Graham
Knoxville
Swain
Madison
Cocke
Sevier
Jefferson
Greene
Washington Carter
Johnson
Sullivan
Hawkins
Hancock
Lee Scott Washington Grayson
Patrick Henry
Pittsylvania Halifax
Mecklenburg
Brunswick
Carroll
Hamblen Grainger Union
Knox
Blount
Mitchell
Yancey
Cleveland
Polk
Iredell
Anson
Stanly
Mecklenburg
Union
Cabarrus
Lincoln
Gaston
Rowan
Brunswick
New Hanover
Pender
Duplin
Onslow
Carteret
Pamlico
Beaufort
Pitt
Hyde
Martin
Hertford
Gates
Perquimans
Bertie
Camden    
Currituck
Washington Tyrrell Dare
Stephens ens
White
mpkin
Banks
Hall
Jackson
Barrow
Oconee Oglethorpe
Athens
Madison
Hart
Franklin
Elbert
Union 
Saluda
McCormick McC
Newberry
Laurens
Anderson
Greenwood
Abbeville
Whit
m
1,001
101
A
1 AIAN
Asian
AA Multiple
NHOPI
Unknown/
NR
Caucasian
1,001
101
1
Non-Hispanic/
non-Latino
Hispanic/Latino
1,001
101
1
Male
Female
B
C
VIRGINIA
NORTH CAROLINA
SOUTH CAROLINA
TENNESSEE
VIRGINIA
NORTH CAROLINA
SOUTH CAROLINA
TENNESSEE
VIRGINIA
NORTH CAROLINA
SOUTH CAROLINA
TENNESSEEChulada et al.
1526  v o l u m e  119 | n u m b e r 11 | November 2011  •  Environmental Health Perspectives
In the second example, viable mono  nuclear 
cells were isolated from the blood of subjects 
with SNPs in ApoE, ABCA1, and other genes 
that regulate cholesterol trafficking and immune 
response (Mahley and Rall 2000; Singaraja 
et al. 2003); these cells were then used to test 
the potential of SNPs to alter inflammatory 
response following ex vivo bacterial lipopolysac-
charide challenge. In both the first and second 
examples, we also recruited appropriate genetic 
controls from the EPR and matched these sub-
jects for sex, race, and ethnicity to subjects with 
the minor alleles. 
The EPR can provide adequate numbers of 
subjects for highly powered cell pheno  typing 
studies such as those described above. To test 
the null hypothesis (no differences between 
geno  types) using t-tests, in the first example 
10 subjects were needed with each geno  type 
to detect a 1.4-fold change in gene expression 
(90% power). In the second example, 9 sub-
jects with each geno  type were needed to detect 
a 1.3-fold change in cytokine (tumor necrosis 
factor-α) levels (85% power). These calcula-
tions assume a significance level of 0.05.
In the third example, we used EPR resources 
at different levels of research, starting with basic 
cell pheno  typing experi  ments that led to com-
prehensive clinical observational studies. First, 
we isolated viable mono  nuclear cells from EPR 
subjects harboring potentially functional SNPs 
in hGR (human glucocorticoid receptor) (Jewell 
and Cidlowski 2007; Schaaf and Cidlowski 
2002). The cells were exposed ex vivo to gluco-
corticoids and examined for immune function 
and gene expression. At the next level, subjects 
with impaired cellular immune function under-
went modified dexa  methasone suppression tests 
to examine the potential of SNPs to alter steroid 
responsiveness. We also examined subjects for 
risk factors (body mass index, hip:waist ratio, 
and blood levels of cortisol, lipids, glucose, 
insulin, and other metabolites), family history 
with emphasis on inflammatory and metabolic 
disease (Manenschijn et al. 2009), and stress. 
The goals were to examine how cells, organs, 
and humans respond to physiological and envi-
ronmental stressors and how polymorphisms in 
hGR affect those responses.
Glucocorticoids that elicit responses through 
hGR regulate numerous homeo  static func-
tions (glucose homeostasis, protein and lipid 
metabolism, skeletal growth, connective tissue 
metabolism, respiratory function, immune sur-
veillance, and behavior) (Ren and Cidlowski 
2005). Glucocorticoids are also among the most 
prescribed drugs in the world and are a primary 
treatment for inflammatory and immune dis-
ease (asthma, arthritis, inflammatory bowel dis-
ease). Chronic elevation of glucocorticoids from 
prolonged stress and/or chronic therapeutic 
administration can have detrimental effects on 
human health. Therefore, by identifying signifi-
cant hGR polymorphisms and understanding 
how they affect gluco  corticoid responsiveness, 
we can identify populations at risk for these 
conditions and/or predict how others might 
respond to gluco  corticoid therapy. Next levels 
in this line of research might include a cohort 
study or personalized medicine trial, both pos-
sible using EPR resources.
The fourth example is a clinical toxicity 
study designed to examine gene × environ-
ment interactions. EPR subjects with func-
tional SNPs in CD44 (receptor for hyaluronic 
acid) and IαI (inter-α-inhibitor) will be 
exposed to ozone via inhalation and exam-
ined for broncho  constrictive responses to 
inhaled metha  choline. In addition, associa-
tions between the SNPs and inflammatory and 
immune markers will be examined in periph-
eral white blood cells and alveolar macro  phages 
collected from the same subjects. In animals 
and humans, both genes have been shown to 
have roles in ozone-induced airway hyper-
reactivity (Garantziotis et al. 2009) and/or   
inflammatory responses in alveolar macro-
phages (McKee et al. 1996). The ultimate 
goal is to identify populations at risk for lung 
inflammation after ozone exposures.
Discussion
Translational research of complex disease 
involves identifying underlying susceptibility loci 
and the environmental factors that affect devel-
opment and/or progression of disease, and then 
applying this information to clinical strategies 
for predicting, preventing, diagnosing, and/or 
treating disease. This process is complicated by 
the fact that complex disease involves multiple 
genes that individually have small pheno  typic 
effects, and the effects of individual genes are 
predicated on environmental triggers and com-
plex pathways. Translational research therefore 
begins by charac  terizing the pheno  typic effect of 
a single locus for some molecular or functional 
change. As new findings emerge, progressively 
higher levels of study evolve that require in vivo 
clinical investigation of individuals with the rel-
evant geno  types and their responses (or resulting 
pheno  types) to environ  mental triggers. Having 
the appropriate tools (DNA, viable tissue, sub-
jects with geno  types of interest) can facilitate the 
translational research process, and that was our 
purpose for developing the EPR.
The EPR is a unique and novel registry 
of subjects and their DNA and was designed 
to facilitate geno  type-driven research of 
environ  mental disease. The EPR Consortium 
was assembled to identify important environ-
mental response genes and design studies to 
test hypotheses concerning gene × environ-
ment inter  actions using EPR resources. In 
deciding which projects to support, preference 
is given to those with potential for identifying 
at-risk populations or where the results are 
applied to clinical practice. For example, in 
the hGR study described above, the results 
will inform scientists about populations at risk 
for multiple conditions after stress. Future 
personalized clinical trials using EPR sub-
jects might help clinicians identify patients 
for whom gluco  corticoid therapy might be 
more effective or toxic. The CD44/IαI study 
described above will identify populations at 
risk for inflammatory lung disease after ozone 
exposure. Preventative strategies might then be 
developed for people living in high-ozone areas 
who carry CD44 and IαI SNPs, or individuals 
who develop inflammatory lung disease might 
be studied for targeted therapies. 
Other types of follow-up studies have been 
conducted (or proposed) using EPR resources 
in addition to those described here. These 
include gene modifier and pharmaco  kinetic 
studies, epidemiological surveys, interventional 
trials, and ethics/opinion surveys. Although the 
EPR is suitable for many types of studies, we 
emphasize that it is not intended for large asso-
ciation or all-inclusive epidemiological studies. 
Instead, the EPR is intended to answer refined 
pheno  typing questions, with narrowly defined 
hypotheses and specific, measurable end points.
Benefits of EPR. The diversity of the EPR 
population is a major benefit. This allows 
scientists to stratify studies by sex, age, race, 
and ethnicity. The EPR has a large minority 
population that consists of 24.7% African 
Americans and 5.3% Hispanics or Latinos. 
Minorities were targeted in the hGR study 
because of a lack of relevant data in these 
populations (Chung et al. 2009; Hawkins 
et al. 2004). The EPR is monitored for racial 
diversity and recruitment is targeted toward 
under  represented groups as needed.
Another benefit is the transparency of 
the informed consent process. Subjects are 
informed verbally and in writing, using plain 
language, of the potential uses of their samples 
and the protections in place to protect their 
privacy. They are made aware that although 
their DNA is coded during phase 1 genetic 
screening, their personal information will be 
shared with scientists for phase 2 follow-up 
studies. They are told to expect to be recon-
tacted each year to update their personal infor-
mation, how often they might be contacted 
for follow-up studies, what participation in 
follow-up studies might entail, and that partici-
pation is voluntary at the time asked. This reas-
sures subjects regarding uncertainties associated 
with future uses of their samples and provides 
them with a solid under  standing of study logis-
tics and goals. Measured EPR response rates at 
study drives (rate of people who sign the writ-
ten consent form following verbal summation) 
are typically > 95%.
A unique feature of the EPR is that 
attrition is minimized by maintaining con-
tinual long-term contact with subjects. To 
date, 80.5% of the EPR population is active, 
meaning they have updated their contact EPR facilitates translational research
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information within the past year and are avail-
able for follow-up studies. Considering that 
recruitment began in 2005, we regard this as 
a success. Furthermore, yearly rates of attrition 
have decreased over time as our methods for 
tracking subjects have become more sophisti-
cated. Subjects are now asked to provide alter-
nate contacts and will soon be recontacted 
by e-mail in addition to the mailings by post 
and phone calls. Subjects also receive biannual 
news  letters that discuss EPR progress, events, 
and follow-up studies [for a copy of the first 
EPR newsletter, see Supplemental Material 
(http://dx.doi.org/10.1289/ehp.1003348)].
Limitations of the EPR. A limitation of 
the EPR is a lack of associated health, family 
history, and other types of data. This will be 
remedied soon: Over the next year we will 
survey EPR subjects about their health status 
and family history. The survey was designed 
with input from consortium members and 
other scientists who have a stake in EPR 
research. In addition, home addresses of EPR 
subjects will be modeled spatially using geo-
spatial information systems (GIS) technology. 
This project is being conducted in collabora-
tion with M.L. Miranda (Nicholas School of 
the Environment and Earth Sciences, Duke 
University) and will allow us to charac  terize 
subjects (based on where they live) for demo-
graphics, culture, health outcomes, environ-
mental quality, chemi  cal exposures, and other 
factors. GIS modeling allows us to visualize 
data in ways that might reveal relation  ships, 
patterns, and trends and can be used to inform 
follow-up study design. Miranda and col-
leagues have previously used GIS modeling 
to predict lead exposure risk levels in North 
Carolina children (Miranda et al. 2002) and 
to identify first Gulf War veterans at risk for 
amyotrophic lateral sclerosis based on toxic 
exposures in Iraq (Miranda et al. 2008).
A potential limitation of the EPR is the 
sampling method used. Subjects were recruited 
in clusters throughout North Carolina as a 
convenience sample, which has advantages 
and disadvantages. The major advantage is that 
subjects can be ascertained quickly and inex-
pensively. This was a consideration in develop-
ing a strategy to recruit 20,000 subjects within 
a relatively short time. A disadvantage is the 
potential for sampling bias. The basis of the 
EPR population is geo  graphy (state of North 
Carolina), and although the EPR is represen-
tative of North Carolina in terms of race and 
ethnicity, its representativeness in other areas 
(socio  economic, health status, other) is not 
known. Although we might conduct limited 
analyses of the EPR as a population-based 
sample, it will primarily be used for smaller 
functional and pheno  typing studies where sub-
jects are selected based on geno  type. Therefore, 
we expect that sampling bias will have only 
small effects on individual follow-up studies. 
Nonresponse bias might be more prob-
lematic. EPR subjects are recruited from the 
general populace via outpatient health care 
clinics, health fairs, community groups and 
gatherings, corporate study drives, and the 
Internet. These types of venues might bias 
the population toward more health-conscious 
individuals and/or fewer individuals with 
disease-causing alleles. This could be com-
pounded further by self-selection at study 
drives. Whether non  response bias will affect 
particular follow-up studies depends on the 
hypothesis and subject recruitment criteria.
Conclusion
Phenotype is commonly used as the basis 
for selecting subjects for biomedical and epi-
demiological research of complex disease. This 
approach is sometimes problematic because 
of broad and heterogeneous phenotypes, poor 
pheno  typing criteria, heterogeneous popula-
tions, selection bias, and a host of other issues. 
Advances in genomic technology combined 
with large-scale genetic repositories are improv-
ing the ways complex diseases are studied, 
and have shifted the basis of subject selection 
toward geno  type. Resources such as the EPR 
are valuable tools in geno  type-driven research 
and can be used to charac  terize variants “from 
bench to bedside” as they are discovered from 
epidemiological research.
The EPR is novel and unique. As a sub-
ject registry and linked DNA biorepository, 
it offers scientists advantages over anonymous 
biorepositories. It provides scientists not only 
DNA to identify potentially significant genetic 
variants but also a readily recontactable and 
diverse population for observational and tox-
icity studies and clinical trials. Once EPR 
subjects have been better charac  terized for 
health status, exposures, lifestyles, and other 
factors, scientists can generate more focused 
study hypothe  ses, design better follow-up 
studies, and select appropriate subpopulations 
to study.
The EPR builds upon the Environmental 
Genome Project (EGP) first launched at the 
NIEHS in 1997 to address the role of genetic 
variation in response to environmental expo-
sure in large populations (Guengerich 1998). 
EGP goals were to identify polymorphisms in 
environmental response genes, study the func-
tional implications of the polymorphisms, 
and associate them with various diseases in 
large population-based studies. The goals of 
the EPR are similar, but the EPR provides 
scientists with better resources for meeting 
these goals and allows scientists to take a flex-
ible, step  wise translational research approach 
into complex disease mechanisms. Knowledge 
of these mechanisms using EPR resources will 
lead to new preventative, diagnostic, and/or 
therapeutic interventions that can significantly 
improve the public’s health.
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